RE:We are totally blowing Keytruda out of the waterTwo treatments (vs 34), excellent safety profile, better efficacy and duration data, already fast-tracked, single-arm ok'd with a smaller patient dataset (if same or better data), ongoing BCG shortage, no debt, proven GMP capability, future rights to new PDs, potential to treat other cancers, high profile advisor. Seems like this should be at $10 already ..and the reason I hold. Just hoping to get that extra clarity on timelines. If the data is good enough (especially safety), FDA should approve this as an adjuvant treatment as well, as opposed to just BCG-resistant NMIBC. Will the next two weeks bring better news? Place your bets.